Lung Cancer Research Review, Issue 25

In this issue:

Pembrolizumab + chemotherapy in metastatic NSCLC
Neoadjuvant nivolumab in resectable lung cancer
Lung cancer more common in young US women vs men
Crizotinib prolongs survival in ALK+ NSCLC
Brigatinib in ALK+ NSCLC and brain metastases
Safety of PD-(L)1 inhibitors in NSCLC with autoimmune disease
Nivolumab promising in pretreated advanced NSCLC
Early mortality after adjuvant chemotherapy for NSCLC
Continue immunotherapy during cranial irradiation
Chemoradiotherapy vs radiotherapy alone in the elderly

Please login below to download this issue (PDF)